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Abstract
The CYP2D family members are instrumental in the metabolism of 20–25% of commonly prescribed drugs. Although many
CYP2D isoforms have been well characterized in other animal models, research concerning the chicken CYP2Ds is limited. In
this study, a cDNA encoding a novel CYP2D enzyme (CYP2D49) was cloned from the chicken liver for the first time. The
CYP2D49 cDNA contained an open reading frame of 502 amino acids that shared 52%–57% identities with other CYP2Ds.
The gene structure and neighboring genes of CYP2D49 are conserved and similar to those of human CYP2D6. Additionally,
similar to human CYP2D6, CYP2D49 is un-inducible in the liver and expressed predominantly in the liver, kidney and small
intestine, with detectable levels in several other tissues. Metabolic assays of the CYP2D49 protein heterologously expressed
in E. coli and Hela cells indicated that CYP2D49 metabolized the human CYP2D6 substrate, bufuralol, but not debrisoquine.
Moreover, quinidine, a potent inhibitor of human CYP2D6, only inhibited the bufuralol 19-hydroxylation activity of CYP2D49
to a negligible degree. All these results indicated that CYP2D49 had functional characteristics similar to those of human
CYP2D6 but measurably differed in the debrisoquine 49-hydroxylation and quinidine inhibitory profile. Further structure-
function investigations that employed site-directed mutagenesis and circular dichroism spectroscopy identified the
importance of Val-126, Glu-222, Asp-306, Phe-486 and Phe-488 in keeping the enzymatic activity of CYP2D49 toward
bufuralol as well as the importance of Asp-306, Phe-486 and Phe-488 in maintaining the conformation of CYP2D49 protein.
The current study is only the first step in characterizing the metabolic mechanism of CYP2D49; further studies are still
required.
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Introduction
Cytochrome P450 monooxygenases (CYPs) are heme-contain-
ing enzymes that are responsible for metabolizing numerous
endogenous and exogenous compounds, including the steroid
hormones, drugs, carcinogens and environmental pollutants [1].
In humans, the CYP2D enzymes are particularly important in
drug metabolism. Members of the CYP2D family constitute 2–4%
of the total hepatic CYPs but are responsible for the metabolism of
20–25% of commonly prescribed drugs [2]. Furthermore,
CYP2Ds exhibit extensive genetic polymorphism, many types
are associated with altered or abolished enzyme activities, which
leads not only to severe adverse effects in clinical therapy but also
to a non-response to medications [3–5].
A large amount of experimental evidences have indicated the
functional importance of CYP2D6 and its variants in humans
[6,7]. Moreover, the crystal structure of human CYP2D6 has been
solved and many important amino acid residues implicated in
substrate recognition and binding have been determined, in-
cluding Phe-120, Glu-216, Asp-301, Phe-481 and Phe-483 [8,9].
Additionally, many isoforms of the CYP2D subfamily other than
human CYP2D6 have been well characterized in animal models of
drug development, such as rats [10–13], mice [14,15], guinea pigs
[16], dogs [17,18], bovines [19], rabbits [20] and monkeys
[21,22]. However, most investigations have focused on their
sequence clonings, biochemical characterizations and catalytic
activities; little is known about their catalytic mechanisms or the
relationships between their functions and structures.
The chicken is one of the most common domestic animals [23].
Defining the contribution of a chicken CYP isoform to the
metabolism of a specific drug is important not only for poultry
pharmacology and toxicology but also for human health because
of the possible presence of poisonous drug metabolites in chicken
products, such as meat and eggs. To date, several important CYPs,
such as CYP1A4/5 [24], CYP3A37 [25] and CYP2C45 [26], have
been cloned and identified in chickens. However, little is known
about the CYP2D isoforms; though studies with chicken liver
microsomes have suggested that CYP2D isoforms are present in
chickens based on the observed metabolism of bufuralol, which is
a prototypical substrate of human CYP2D6 [27].
Here, we describe the cloning, characterization and catalytic
functional studies of a novel chicken CYP2D gene, termed
CYP2D49, which was the first CYP2D gene reported in chickens.
Through studies of its sequence, tissue expression pattern and
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38395inductive properties as well as metabolic characterization, we
found that CYP2D49 had the ability to catalyze bufuralol 19-
hydroxylation and may be a counterpart to human CYP2D6 in
chickens. Furthermore, we studied the catalytic mechanism of
CYP2D49 toward bufuralol and elucidated the key amino acid
residues involved in its enzymatic activity and protein conforma-
tion.
Results
Identification of a novel CYP2D gene from the chicken
liver with similarity to human CYP2D6
To identify the CYP2D isoforms in chickens, we first searched
against the chicken EST database with the human CYP2D6
sequence. This resulted in the discovery of a unique unpublished
cDNA clone (GenBank accession no. CR354312.1). Based on this
discovery, we cloned the coding sequence of the cDNA (GenBank
accession no. JQ241277) from the chicken liver for the first time.
The sequence has been submitted to the Committee on P450
Nomenclature, which suggested the name CYP2D49 for this gene
[25,28]. To demonstrate the genetic distance between chicken
CYP2D49 and other CYP2D isoforms in experimental animal
species, the identities of the respective CYP2D isoforms are
indicated as percentages in Table 1. The deduced 502 amino acid
residues sequence of CYP2D49 possessed 52%–57% identities
with the other CYP2D enzymes (Table 1). This finding, together
with a phylogenetic comparison of the deduced amino acid
sequence of CYP2D49 with the sequences of other CYP2D
isoforms (Fig. 1A), indicated that chicken CYP2D49 belonged to
the CYP2D family, but showed far evolutionary distance to other
CYP2D enzymes because of the remarkable interspecies differ-
ences.
To determine the genomic structure of chicken CYP2D49,w e
further searched the chicken genomic database with the CYP2D49
sequence and compared the gene structure and the neighboring
genes of chicken CYP2D49 to those of human CYP2D6. As shown
in Fig. 1B, CYP2D49 localized in chromosome 1 and is composed
of nine exons and eight introns; additionally, its exon–intron
organization as well as the corresponding sizes of these segments
and the coding region boundaries are conserved and similar to
those of human CYP2D6 (Fig. 1B). Furthermore, we found a set of
genes neighboring CYP2D49 that demonstrate highly conserved
synteny to human CYP2D6 (Fig. 1B). These results suggest that
CYP2D49 may be the chicken counterpart to human CYP2D6.
Expression of recombinant CYP2D49 protein and
detection of the specificity of anti-CYP2D49 antiserum
To study the function of the CYP2D49 protein, the recombi-
nant protein was expressed in a prokaryotic expression system. As
shown in Fig. 2A, a Myc-His-tagged fusion CYP2D49 protein of
approximately 55 kDa was expressed (Lanes 2 and 3) and
successfully purified by Ni
2+-NTA affinity chromatography (Lane
4). Western blotting detection using an anti-Myc antibody further
confirmed the correction of the recombinant expression (Fig. 2B).
To further characterize the expression patterns of CYP2D49 at
the protein level, a polyclonal anti-CYP2D49 antiserum was
generated by immunizing mice with the purified CYP2D49
protein. Western blotting results showed that this anti-CYP2D49
antiserum (Fig. 2C, lane 2), but not the pre-immune mouse serum
(Fig. 2C, lane 1), was able to recognize over-expressed CYP2D49
to provide a specific band at 55 kDa. Moreover, the band is
recognized by the anti-Myc antibody (Fig. 2C, lane 4) but not by
the anti-CYP2D49 antiserum that had been pre-adsorbed with
excess antigen (purified CYP2D49-Myc-His-tag fusion protein)
(Fig. 2C, lane 3). These results indicate that the generated
antiserum can recognize CYP2D49 with high specificity.
In vivo and in vitro expression patterns of CYP2D49
To determine the distribution of CYP2D49 in chicken tissues,
real-time PCR and western blotting analyses were performed on
nine tissues. As shown in Fig. 3A, CYP2D49 was ubiquitously
distributed at the mRNA level in all normal tissues assayed. It was
predominantly expressed in the liver, kidney and small intestine,
with lower transcription levels in the brain, lung, heart, spleen,
testis and ovary. Using the generated anti-CYP2D49 antiserum,
the expression of CYP2D49 at the protein level was further
analyzed. As shown in Fig. 3B, CYP2D49 protein exhibited
similar expression patterns to its transcription patterns, with
protein expression occurring predominantly in the liver, kidney
and small intestine, along with weak expression in the testis and
ovary. If extending the exposure time, weaker bands could be
detected in the brain, lung, heart and spleen (data not shown).
To investigate the inductive properties of chicken CYP2D49 in
vitro, Leghorn male hepatocellular carcinoma epithelial (LMH)
cells were treated with four representative CYP inducers
(rifampicin, clotrimazole, b-naphthoflavone and dexamethasone)
and a candidate substrate of CYP2D49 (bufuralol). As shown in
Fig. 3C, no induction was detectable after the treatments with the
five drugs at three time points; this finding demonstrates that
CYP2D49 in the liver is not inducible.
Enzymatic properties of recombinant CYP2D49 protein
The solubilized membrane fraction of E. coli cells transformed
with pCWOri-CYP2D49 showed typical reduced CO-difference
spectra that exhibited Soret peaks at 450 nm (Fig. 4A). However,
no absorption at 450 nm was observed in the solubilized
membrane fraction of E. coli cells transformed with the
corresponding empty vector (date not shown). These results
indicate that partial CYP2D49 proteins heterologously expressed
in E. coli form holoenzymes and exhibit natural catalytic activities.
To further determine the enzymatic properties of CYP2D49,
metabolic assays of the purified CYP2D49 protein were performed
using the typical human CYP2D6 substrates, bufuralol and
debrisoquine [29]. As shown in Fig. 4B and 4C, recombinant
CYP2D49 protein exhibited bufuralol 19-hydroxylation activity.
The formation of 19-hydroxybufuralol was observed to follow
simple Michaelis–Menten kinetics (Fig. 4B). The Km value was
calculated as 3.94860.232 mM [mean 6 standard deviations
(SD)] and the Vmax value was calculated as 361.364.261 nmol
min
21 mg
21 protein (mean 6 SD) (r
2=0.99; Fig. 4B). In addition,
Eadie–Hofstee plot analysis revealed that the activity of recombi-
nant CYP2D49 enzyme followed a monophasic kinetic pattern
(r
2=0.97; Fig. 4C). These results demonstrate that the purified
CYP2D49 is enzymatically active and can efficiently metabolize
bufuralol. However, we did not detect any catalytic activity of the
recombinant CYP2D49 protein toward debrisoquine (data not
shown).
Quinidine is a potent inhibitor of human CYP2D6 and has
been widely used as a probe of CYP2D inhibition in other animal
species [13,22,30]. However, low concentrations of quinidine
showed a negligible or low inhibitory effect toward the bufuralol
19-hydroxylation activity of CYP2D49 (data not shown). Though
increasing the concentration of quinidine from 10 mMt o5 0mM,
the inhibitory effect is still weak (Fig. 4D).
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bufuralol
Studying the influence of key amino acid residues on the
catalytic activity of an enzyme may shed light on its catalytic
mechanism. In human CYP2D6, amino acid residues such as Phe-
120, Glu-216, Asp-301, Phe-481 and Phe-483 have been proposed
to be involved in the substrate recognition and binding (Fig. 5A).
To investigate whether the above five amino acid residues are also
important for the bufuralol 19-hydroxylation activity of CYP2D49,
site-directed mutagenesis studies were conducted. We first aligned
partial amino acid sequences of chicken CYP2D49 to that of
human CYP2D6 and found that CYP2D49 owned the same
amino acid residues as human CYP2D6 at all the sites except for
the position 126, which is replaced by a valine residue (Fig. 5B).
We then prepared plasmids encoding wild-type and mutant
CYP2D49 (pcDNA-CYP2D49-V126A, V126F, E222A D306A,
F486A and F488A) and transiently transfected them into Hela
cells. Western blotting analysis was used to determine whether the
transient transfection was successful. As shown in Fig. 5C, the
transient transfection with WT and mutant CYP2D49 plasmids
led to the significant over-expression of proteins with an estimated
molecular mass of 55 kDa; these proteins were not detectable in
control cells. The amount of CYP2D49 and its mutants detected
was normalized against the detected amount of b-actin (data not
Figure 1. Phylogenetic tree of CYP2D amino acid sequences and genomic structures of human CYP2D6 and chicken CYP2D49. (A)
Phylogeny of CYP2D amino acid sequences from the chicken and other animal species. The neighbor-joining tree was created using the Molecular
Evolutionary Genetics Analysis Version 4 software. The numbers on the branches indicate the number of times per 100 bootstrap replicates that the
branch appeared in the trees, estimated by a random resampling of the data. Only bootstrap values greater than 50% are shown. The scale bar
represents 5 substitutions in 100 residues. (B) Genomic structures of human CYP2D6 and chicken CYP2D49. The diagram of the organization of the
CYP2D subfamily in humans and chickens was determined by the BLAT analysis of the human and chicken genome data from NCBI database. Exons
are indicated by boxes, whereas introns are indicated by lines. The lengths of the exons and introns are expressed in base pairs. The arrowheads
indicate the direction of transcription.
doi:10.1371/journal.pone.0038395.g001
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the over-expressed WT and variant CYP2D49 proteins were
determined by incubating bufuralol with S9 fractions from Hela
cells which were transfected with empty vector, WT CYP2D49
and six CYP2D49 mutants. As shown in Fig. 5D, the WT
CYP2D49 protein exhibited distinct bufuralol 19-hydroxylation
activity comparing to the control. However, significant decreases
in the bufuralol 19-hydroxylation activity were observed for all the
variants, especially for the D306A variant (Fig. 5D). The bufuralol
19-hydroxylation activities [V(nmol/min/mg protein)] of the WT
CYP2D49 and the V126A, V126F, E222A, D306A, F486A and
F488A variants were 309.7766.14, 44.9161.09, 18.1760.53,
123.7160.98, 2.0760.70, 88.5161.24 and 82.3864.70 (mean 6
SD), respectively, which indicates that these amino acid residues
may play important roles in the bufuralol 19-hydroxylation activity
of chicken CYP2D49.
Circular dichroism spectroscopy analysis
The circular dichroism (CD) spectroscopy analysis is an
excellent tool for the rapid determination of the secondary
structure and folding properties of proteins [32]. To elucidate
the relationship between the function and the structure of
CYP2D49 protein, we further expressed and purified the six
CYP2D49 variants from E. coli cells and investigated the changes
of their physicochemical characterizations by CD spectroscopy
analyses. As shown in Fig. 6A, the CD spectra of CYP2D49 WT
and its variants exhibited the characteristic signature of an a helix
with minima at 222 and 208 nm. The helical contents of the
V126A, V126F, E222A, D306A, F486A, F488A variants as well as
the WT protein were 38.2%, 39.8%, 33.3%, 23.9%, 50.3%,
18.1% and 37.9%, respectively. The helical content of the F486A
variant was much higher than that of the WT CYP2D49, whereas
the helical contents of the D306A and F488A variants were much
lower (Fig. 6A). In addition, based on the mean residue ellipticity
at 222 nm of a 5 mM protein preparation in 100 mM potassium
phosphate (pH 7.4) at 4uC, the melting temperature (Tm) of the
WT CYP2D49 was 59uC (Fig. 6B). At the same concentration, all
variants displayed a cooperative thermal unfolding transition with
Table 1. Comparison of the deduced amino acid sequence of
CYP2D49 with the sequences of other CYP2D isoforms.
Species Forms Identity Accession No.
Chicken CYP2D49 100% AEZ51809
Rat CYP2D3 57% J02868
Human CYP2D6 56% M33388
Bovine CYP2D14 57% X68481
Dog CYP2D15 54% D17397
Guinea pig CYP2D16 52% U21486
Cynomolgus monkey CYP2D17 56% U38218
Marmoset CYP2D19 55% D29822
Hamster CYP2D20 56% D86476
Miniature pig CYP2D21 57% D89502
Mouse CYP2D22 53% AF221525
Rabbit CYP2D24 53% AB008785
Pig CYP2D25 56% Y16417
Japanese monkey CYP2D29 55% AF301911
Marmoset CYP2D30 55% AY082602
doi:10.1371/journal.pone.0038395.t001
Figure 2. Expression of recombinant CYP2D49 protein and
detection of the specificity of anti-CYP2D49 antiserum. (A)
Proteins were analyzed by SDS-PAGE on 10% Tris-Glycine gels stained
with Coomassie brilliant blue R-250. Lane 1: non-IPTG-induced bacteria;
lane 2: IPTG-induced total cell lysates; lane 3: supernatant of the IPTG-
induced cell lysates and lane 4: the protein purified by Ni
2+-NTA affinity
chromatography. (B) Western blotting analysis was used to confirm
whether the prokaryotic expression of CYP2D49 protein had succeeded.
The protein samples described in Fig. 2A were detected by the anti-Myc
antibody. Lane 1: non-IPTG-induced bacteria; lane 2: IPTG-induced total
cell lysates; lane 3: supernatant of the IPTG-induced cell lysates and lane
4: the protein purified by Ni
2+-NTA affinity chromatography. (C) The
protein samples extracted from Hela cells which were transiently
transfected with pcDNA-CYP2D49 were separated by SDS-PAGE and
immunoblotted using different antibodies. Lane 1: the normal mouse
serum; lane 2: the polyclonal anti-CYP2D49 antiserum; lane 3: the anti-
CYP2D49 antiserum pre-adsorbed with excess antigen (purified
CYP2D49 protein); lane 4: the anti-Myc antibody.
doi:10.1371/journal.pone.0038395.g002
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melting temperature was decreased to 50uC (Fig. 6B).
Discussion
Chicken liver microsomes exhibit bufuralol 19-hydroxylation
activity, which indicates the existence of CYP2D isoenzymes in
chickens [27]. However, chicken CYP2D isoforms have not been
previously identified. This prompted us to search for cDNA
sequences of chicken CYP2Ds in the NCBI database and led to the
successful identification of CYP2D49, which is the first reported
avian CYP2D isoenzyme. Here, we studied the genomic
organization, in vivo and in vitro expression patterns and metabolic
properties of CYP2D49 and we further elucidated its probable
metabolic mechanism toward bufuralol.
Human CYP2D6 is a part of the CYP2D gene cluster with two
inactive pseudogenes, CYP2D7P and CYP2D8P [33,34]. However,
these two pseudogenes are not found in the corresponding
genomic region neighboring chicken CYP2D49. The different
numbers of genes in the CYP2D cluster in humans compared with
the chicken are probably the results of the gene duplications of the
P450s, including CYP2Ds, that have occurred in each species
during evolution [35]. To find out whether there is any other
CYP2D existed in chickens, we used the sequence of CYP2D49 to
search for its homologues in the chicken EST and genomic
database but none was found. Thus, CYP2D49 appears to be the
best candidate ‘‘orthologue’’ of CYP2D6 in chickens. However, we
cannot exclude the possibility that there are other CYP2Ds in
chickens due to incomplete EST and genomic information.
The expression data indicate that CYP2D49, similarly to
CYP2D6, is highly expressed in the liver, kidney and small
intestine and modestly expressed in various other tissues [30]. The
specific tissue distribution of chicken CYP2D49 suggests that
CYP2D49 protein may have specific catalytic properties and play
specific roles in the liver, kidney and small intestine. Based on
these, we further studied the inductive characterization of
CYP2D49 in the liver. In humans, CYP1A1, CYP1A2, CYP2B6,
CYP2C8, CYP2C9, CYP2C19 and CYP3A4 are known to be
inducible, whereas CYP2D6 is not [30]. Rifampicin, b-naphtho-
flavone, dexamethasone and clotrimazole are representative CYP
inducers and can induce the expression of chicken CYP3A37,
CYP2H1 and CYP2C45 in LMH cells, the first continuously
dividing cell line of the chicken liver [26,36,37]. However, none of
these inducers can increase the expression of CYP2D49 in LMH
cells. CYPs are often induced by their own substrates to allow
a dynamic adaptation to xenobiotic exposure [38]. However, the
candidate substrate of CYP2D49 (bufuralol) also failed to induce
the expression of CYP2D49. All these indicate that CYP2D49 is
not inducible in the liver, similar to human CYP2D6. Further
studies are still required to demonstrate the regulational mechan-
isms of the in vivo and in vitro expression patterns of CYP2D49.
Recombinant CYP2D49 protein expressed from either pro-
karyotic or eukaryotic systems effectively hydroxylated bufuralol,
as typically observed for human CYP2D6 [29]. Moreover, the Km
value of CYP2D49 for bufuralol 19-hydroxylation reaction
(3.94860.232 mM) is similar to that of human CYP2D6
(4.4 mM) [39]. All these further confirm our notion that chicken
CYP2D49 is an orthologue of human CYP2D6 and indicate that
CYP2D49 may have similar bufuralol binding affinity to human
CYP2D6. However, the Km value of CYP2D49 for bufuralol 19-
hydroxylation reaction is much lower than that of the chicken liver
microsomes reported by Khalil et al., who also investigated the
kinetic parameters of dog liver microsomes for bufuralol parallel
[27]. We found that the Km value of dog liver microsomes for
bufuralol 19-hydroxylation reaction [27] is higher than the value
reported by Roussel et al [31]. Thus, further studies are still needed
to confirm the enzymatic kinetics of chicken liver microsomes for
bufuralol and the critical role of CYP2D49 in this reaction.
Clear differences exist between humans and other animal
species with regard to the phase I and phase II drug metabolic
reactions [30]. Though our data from the genomic organization, in
vivo and in vitro expression patterns and metabolic properties of
CYP2D49 indicate that chicken CYP2D49 is an orthologue of
human CYP2D6, these differences are also observed between
chicken CYP2D49 and human CYP2D6. For example, recombi-
nant CYP2D49 showed inefficient debrisoquine 49-hydroxylation
activity, which is another typical representative reaction of human
CYP2D6 [21]. Indeed, rat CYP2D3 and CYP2D4 are also
deficient in their ability to metabolize debrisoquine, which is
Figure 3. In vivo and in vitro expression patterns of CYP2D49.
(A) CYP2D49 transcripts in the indicated tissues of the healthy chicken
were detected by real-time PCR amplification. The expression of the
target gene was calculated relative to that of 18S rRNA according to the
2
2DCT method. Error bars represent standard deviations obtained by
measuring each sample in triplicate. He-Heart; Li-Liver; Sp-Spleen; Lu-
Lung; Ki-Kidney; Br-Brain; Sin-Small intestine; Te-Testis; Ov-Ovary. (B)
The lysates of the above chicken tissues were separated by 10% SDS-
PAGE and then stained by Coomassie brilliant blue R-250 for
normalization of sample loadings. Western blotting analysis using
anti-CYP2D49 antiserum was exploited to detect the expression of
CYP2D49 at the protein level. (C) LMH cells were treated with rifampicin,
clotrimazole, b-naphthoflavone, dexamethasone and bufuralol for 24,
48 and 72 h, respectively. Real-time PCR was used to detect the levels of
CYP2D49 mRNA. The ratio of CYP2D49 to b-actin in control cells was set
to 1 and the values in all treated cells were normalized relative to this
value. The experiments were conducted in triplicate and the data are
expressed as the mean 6 SD.
doi:10.1371/journal.pone.0038395.g003
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chicken has lost the ability to transform debrisoquine or if other
CYPs are responsible for this reaction requires further study. In
addition, quinidine, a prototypical inhibitor of human CYP2D6
[13,30], showed a negligible inhibitory effect toward the bufuralol
19-hydroxylation activity of CYP2D49. In fact, the inhibition
profiles of the rat, monkey and mouse proteins also differ from that
of the human protein. Bogaards et al. reported a negligible (in the
rat and mouse) or low (in the monkey) inhibitory effect by
quinidine toward bufuralol 19-hydroxylase catalytic activity [41].
Most substrates of CYP2D6 include an aromatic moiety and
a basic nitrogen atom in their structures. Site-directed mutagen-
esis, computational modeling and the crystal structure of human
CYP2D6 identified the importance of Phe-120, Glu-216, Asp-301,
Phe-481 and Phe-483 in substrate recognition and binding [8,9].
Glu-216 and Asp-301, which are two negatively charged residues
in the active site of human CYP2D6, facilitated the binding and
orientation of the ligands in the active site through the formation
of an electrostatic interaction between their carboxylate group and
the basic nitrogen atom of the CYP2D6 substrates [42,43].
Additionally, the aromatic side chains of Phe-120, Phe-481 and
Phe-483 interacted with the aromatic moiety of the substrate
through a hydrophobic (p-p) interaction [9,44–46]. Each mutation
of the position 222, 306, 486 and 488 in CYP2D49 to a neutral
alanine residue greatly decreased the catalytic efficiency of
CYP2D49 toward bufuralol, especially for the mutation D306A.
This finding indicates that these four amino acid residues are
important for the bufuralol 19-hydroxylation activity catalyzed by
CYP2D49. Further studies are still needed to confirm whether the
four sites in CYP2D49 function in the same way to that of human
CYP2D6.
It is interesting to note that Phe-120 is not conserved in
CYP2D49; rather, it is replaced by a valine residue. In fact, rat
CYP2D2, CYP2D3 and CYP2D4 possess a valine instead of
a phenylalanine at position 120 and exhibit normal bufuralol 19-
hydroxylation activity [47]. We then mutated this position to an
alanine or a phenylalanine; both mutations decreased the catalytic
activity of CYP2D49 toward bufuralol. These results demonstrate
that Val-126 is also important for the catalytic activity of
CYP2D49 toward bufuralol. Although Phe-120 was considered
to be important in orienting the aromatic ring of most substrates
with respect to the heme moiety of the enzyme, no change was
found in the apparent Km or Vmax values for bufuralol oxidation
catalyzed by human CYP2D6 F120A variant [45]. Thus, the
Figure 4. Enzymatic properties of recombinant CYP2D49 protein. (A) Reduced CO-difference spectrum of recombinant CYP2D49 (solubilized
membrane fraction). The spectrum was measured in 200 mM Tris-HCl buffer (pH 7.4) containing 40% glycerol and 2 mM EDTA. No absorption at
approximately 450 nm was observed in the solubilized membrane fraction of E. coli cells transformed with the corresponding empty vector. (B)
Michaelis–Menten plot and (C) Eadie–Hofstee plot of the bufuralol 19-hydroxylation activity of recombinant CYP2D49 enzyme. The incubation and
reaction were processed essentially as described under ‘‘Materials and methods’’ and the enzyme kinetic parameters of CYP2D49 were determined by
HPLC. Each point and bar represents the mean 6 SD of three replicates. (D) Inhibitory effect of quinidine on the bufuralol 19-hydroxylation activity of
recombinant CYP2D49 enzyme. For quinidine inhibition studies, the incubation were performed by pre-incubating purified CYP2D49 protein for
5 min at 37uC with 100 mM bufuralol and varying concentrations of quinidine. The reactions were then started by the addition of NADPH. The data
detection and analysis were processed essentially as described under ‘‘Materials and methods’’. Each point and bar represents the mean 6 SD of
three replicates.
doi:10.1371/journal.pone.0038395.g004
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activity of human CYP2D6 when the substrate is bufuralol.
Additionally, Narimatsu et al. found that rat CYP2D4 V123F
variant showed increased Km values and decreased Vmax values for
bufuralol oxidation, indicating that Val not Phe at position 123 is
important for the catalytic activity of CYP2D4 toward bufuralol
[48]. They speculated that bufuralol with a basic nitrogen atom
can be captured ionically by the carboxylate group of Glu-219 or
Asp-304 (corresponding to Glu-216 and Asp-301 of human
CYP2D6), resulting in an orientation whereby the oxidation site
Figure 5. Enzymatic activities of six CYP2D49 variants towards
bufuralol. (A) Crystal structure of human CYP2D6. The conformation
was constructed based on the crystallographic data of CYP2D6 (2F9Q)
obtained from Protein Data Bank and drawn using Accelrys ViewerLite
Version 5.0. Amino acid residues at positions 120, 216, 301, 481 and 483
are in ball-and-stick form. (B) Alignment of the partial amino acid
sequences of human CYP2D6 and chicken CYP2D49. The number at the
top is for human CYP2D6; the number at the bottom is for chicken
CYP2D49. The arrowheads show the amino acid residues to be
substituted. (C) Functional expression and detection of WT CYP2D49
and its variants. S9 fractions from Hela cells which were transfected with
empty vector, pcDNA-CYP2D49, pcDNA-CYP2D49-V126A, V126F, E222A,
D306A, F486A and F488A were extracted and separated on 10% SDS-
PAGE gels. Western blotting analysis was then used to confirm that
transient transfection had succeeded. Blots were probed with the anti-
CYP2D49 antiserum and a b-actin antibody, respectively. (D) Bufuralol
19-hydroxylation catalytic activities of six CYP2D49 variants. S9 fractions
of Hela cells which were transfected with empty vector, WT CYP2D49
and six CYP2D49 mutants were incubated with bufuralol as described in
‘‘Materials and methods’’. Metabolites produced in the reactions were
analyzed by HPLC. The data are represented as nanomoles of
metabolite/min/microgram of protein. The data shown are derived
from a representative experiment reported as the mean (n=3) 6 SD.
Differences between the WT and mutant protein samples are significant
when ** p,0.01.
doi:10.1371/journal.pone.0038395.g005
Figure 6. Physicochemical analyses of WT CYP2D49 protein
and its variants. (A) The CD spectroscopy was used to analyze the
secondary structures of the WT CYP2D49 protein and its variants.
Proteins purified from E. coli were assayed at a final concentration of
5 mM in 0.1 M potassium phosphate (pH 7.4). The CD spectra were
acquired at 4uC on the Chirascan. (B) The thermal melt was monitored
by CD spectroscopy using the same proteins described in Fig. 6A.
Thermal denaturation was monitored at 222 nm by applying a thermal
gradient of 2uC/min over the range from 4–92uC.
doi:10.1371/journal.pone.0038395.g006
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the mutated Phe at position 123 captures bufuralol via hydropho-
bic (p-p) interaction between the aromatic rings of Phe-123 and
bufuralol, lowering the efficacy of the bufuralol oxidation by
interfering with the interaction of other bufuralol molecules with
the carboxylate group of Glu-219 or Asp-304. The CYP2D49
V126F variant may function in the same way to that of rat
CYP2D4. However, further studies are still needed to explore the
exact mechanism.
Furthermore, CD spectroscopy was used to analyze the effect of
site-directed mutagenesis on the secondary structure of CYP2D49
and to reveal the relationship between the function and the
structure of CYP2D49. All six mutations decreased the ability of
CYP2D49 to metabolize bufuralol. However, only D306A, F486A
and F488A variants changed the a-helical content of CYP2D49
protein and the F486A variant decreased the Tm value of
CYP2D49 protein. These results demonstrate that Asp-306, Phe-
486 and Phe-488 may play critical roles in maintaining the
conformation of CYP2D49 protein; mutations at these sites may
break the natural structure of CYP2D49 protein and lead to great
decrease in the catalytic efficiency of CYP2D49 toward bufuralol.
Moreover, both V126A and V126F mutations have no influence
on the secondary structure and thermal stability of CYP2D49,
suggesting that Val-126 may not function through maintaining the
conformation of CYP2D49 protein. However, how exactly Val-
126 affects the catalytic activity of CYP2D49 toward bufuralol still
needs further study.
The relationship between enzymatic activity and protein
structure and stability is very complicated. Any change of the
structure of an enzyme could affect its catalytic activity to some
extent, however, protein structure and stability is not the only
factor influencing its activity. The key sites of an enzyme can also
function through direct interactions with the substrates. Besides
breaking the natural structure of CYP2D49 protein, the D306A
variant may destroy the electrostatic interaction between carbox-
ylate group of Asp-306 and the basic nitrogen atom of bufuralol,
which inhibited the oxidation site (19-position) of bufuralol coming
close to the heme iron and resulted in great decrease of the
catalytic efficiency of CYP2D49 toward bufuralol. However, the
F486A variant may mainly change the conformation of CYP2D49
and lead to the decrease in the catalytic efficiency of CYP2D49
toward bufuralol to a less extent. All these speculations still need
more experimental evidences.
In conclusion, we have found a novel and also the first CYP2D
gene in the chicken. Studies of its sequence, tissue expression
pattern, inductive properties and metabolic characteristics show
that CYP2D49 can catalyze the 19-hydroxylation of bufuralol and
may be a counterpart to human CYP2D6 in chickens. Further
investigations of the metabolic mechanism of CYP2D49 identified
the importance of Val-126, Glu-222, Asp-306, Phe-486 and Phe-
488 in keeping the enzymatic activity of CYP2D49 toward
bufuralol as well as the importance of Asp-306, Phe-486 and Phe-
488 in maintaining the conformation of CYP2D49 protein. The
current study is only the first step in characterizing the metabolic
mechanism of CYP2D49; further studies are still required.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Regulations for the Administration of
Affairs Concerning Experimental Animals of Guangdong Prov-
ince, China. The protocol was approved by the Committee on the
Animal Care and Use of Laboratory Animal Center of Sun Yat-
sen University (Production Permit Number: SCXK 2004-0011;
Use Permit Number: SYXK 2007-0081). All efforts were made to
minimize suffering.
Chemicals and reagents
Bufuralol hydrochloride, 19-hydroxybufuralol, debrisoquine and
49-hydroxydebrisoquine were purchased from TRC (North York,
Ontario, Canada). NADPH-P450 reductase, cytochrome b5,
NADPH, quinidine, rifampicin, b-naphthoflavone, clotrimazole
and dexamethasone were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Acetonitrile (ACN) and water used for high-
performance liquid chromatography (HPLC) were obtained from
Thermo Fisher Scientific (Fairlawn, NJ, USA) and Milli-Q Ultra-
purification Systems (Millipore, Bedford, MA, USA), respectively.
All the other chemicals and reagents used were of analytical grade.
Animals and cell culture
Three-yellow broilers (three males and three females, 7–8 weeks
old, 1.2–1.5 kg) were purchased from the College of Veterinary
Medicine at South China Agricultural University (SCAU).
Chicken tissues for RNA and protein preparation were collected,
snap-frozen in liquid nitrogen and stored at 280uC until use.
BALB/c mice (five males, 5–6 weeks old) were used to generate
polyclonal anti-CYP2D49 antiserum and purchased from the
Laboratory Animal Center of Sun Yat-sen University (SYSU). The
chickens and mice were fed commercial standard diets and were
allowed access to water ad libitum to ensure the absence of
therapeutic or illicit treatments before slaughtering.
Hela cells (ATCC, CCL-2) and LMH cells (ATCC, CRL-2117)
were maintained at 37uC in Dulbecco’s Modified Eagle’s Medium
(DMEM) and William’s E medium (Sigma-Aldrich, St. Louis,
MO, USA), respectively, that were supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml strep-
tomycin. For induction, the LMH cells were treated with
concentrations of 25, 10, 10, 25 and 100 mM, respectively, of
rifampicin, clotrimazole, b-naphthoflavone, dexamethasone and
bufuralol, which were dissolved in DMSO (Sigma-Aldrich, St.
Louis, MO, USA). After treatment for 24, 48 and 72 h, the cells
were collected for RNA extraction. The control cells were
incubated in equal solvent concentrations.
cDNA cloning and the construction of plasmids
Total RNA from the chicken liver was extracted with the SV
Total RNA Isolation System (Promega, Madison, WI, USA) and
first-strand cDNA was synthesized using SMART MMLV Re-
verse Transcriptase (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. The cDNA encoding chicken
CYP2D49 was amplified by polymerase chain reaction (PCR) from
the single-stranded cDNA template using the following primers:
59-CGGGGAGGGGAGCAGGAGAA-39 (sense) and 59-
CGCAGGAACTCAGGACTAAAAC-39 (antisense). These pri-
mers were designed based on the nucleotide sequence of the
flanking region of the chicken finished cDNA clone
CHEST77m14 (GenBank accession no. CR354312.1). The PCR
product was cloned into the pMD20-T vector (TaKaRa, Qingdao,
China) and verified by DNA sequencing. The deduced sequence
was submitted to the P450 nomenclature committee for name
designation and then to GenBank (accession no. AEZ51809).
To allow functional expression in E. coli, the N-terminal coding
region of CYP cDNA requires a modification, for which we
selected ompA+2 according to the Cytochrome P450 Protocols
[49]. Briefly, a cDNA fragment encoding the bacterial ompA leader
sequence (21 amino acid residues) and two additional spacer
amino acid residues (Leu-Glu) were fused to the CYP2D49
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inserted into the Not I/Kpn I sites of the pCWOri+ vector
(pCWOri-CYP2D49). To allow eukaryotic expression, the open
reading frame (ORF) region of CYP2D49 was inserted into the Not
I/Hind III sites of the pcDNA
TM3.1/myc-His (2) A (Invitrogen,
Carlsbad, CA, USA) vector (pcDNA-CYP2D49). Six mutants
(pcDNA-CYP2D49-V126A, V126F, E222A, D306A, F486A and
F488A) were prepared from pcDNA-CYP2D49 using the Quik-
Change Site-directed Mutagenesis Kit (Invitrogen, Carlsbad, CA,
USA). The mutant cDNAs from pcDNA
TM3.1/myc-His (2)A
were then subcloned into the pCWOri+ vector using primers
containing Not I/Kpn I sites. All plasmids were verified by DNA
sequencing.
Recombinant protein expression and preparation of anti-
CYP2D49 antiserum
The expression plasmid pCWOri-CYP2D49 was transformed
into DH5a competent cells. A single clone was randomly picked
and cultured at 37uC for 5–7 h in LB media containing 100 mg/L
ampicillin first and then used to inoculate modified TB media
(12 g/L bactotryptone, 24 g/L yeast extract, 2 g/L bactopeptone
and 4 ml/L glycerol) containing 100 mg/L ampicillin and
1.0 mM thiamine with supplementation of trace elements. IPTG
was added at a final concentration of 1 mM when the OD600 of
the cell culture reached 0.7–0.8 and the expression of recombinant
CYP2D49 was then induced at 30uC for 36 h. The cultures were
then chilled on ice and centrifuged at 2,8006g for 20 min at 4uC.
The cell pellet was re-suspended in 100 mM Tris acetate buffer
(pH 7.6) containing 500 mM sucrose and 0.5 mM EDTA and the
suspension was then diluted with an equal volume of ice-cold
water. Lysozyme was added to the re-suspended cells at a final
concentration of 0.25 mg/ml. The suspension was incubated at
4uC for 45 min with agitation. The spheroplasts were pelleted at
2,8006g for 20 min at 4uC and re-suspended in 100 mM
potassium phosphate buffer (pH 7.6) containing 6 mM magne-
sium acetate, 20% glycerol (v/v) and 0.1 mM DL-dithiothreitol.
The suspensions were sonicated on ice and centrifuged at
12,0006g for 20 min at 4uC. The supernatants were pipetted
into ultracentrifuge tubes and centrifuged at 220,0006g for 60 min
at 4uC. The membrane pellets were dissolved in ice-cold MCAC-
0 buffer (pH 7.4) containing 20 mM Tris, 500 mM NaCl, 1%
Triton X-100 (v/v) and 20% glycerol (v/v). The solubilized
membrane fraction containing CYP2D49 was loaded onto
a nickel-charged NTA-agarose column (HisTrap HP, 5 ml, GE,
USA) and purified by fast protein liquid chromatography (FPLC)
(AKTA purifier, GE, USA) according to the manufacturer’s
instructions. The same methods were used to express and purify
the six CYP2D49 variants (pCWOri-CYP2D49-V126A, V126F,
E222A, D306A, F486A and F488A).
In metabolic assays, the reduced CO-difference spectrum of
recombinant CYP2D49 (solubilized membrane fraction) was
measured spectrophotometrically according to the Cytochrome
P450 protocols [49]. The protein concentrations were determined
by the Bradford method. For CD spectra, all purified proteins
were further dialyzed in 100 mM potassium phosphate buffer
(pH 7.4) overnight.
Purified CYP2D49 protein was also used to immunize mice to
raise polyclonal anti-CYP2D49 antiserum according to the
protocol of a previous report [50]. Briefly, prior to a course of
immunization, approximately 0.2 ml of blood was collected from
the mouse to provide a source of pre-immune antiserum. One
week later, approximately 300 mg of purified CYP2D49 protein
emulsified in complete Freund’s adjuvant was injected sub-
cutaneously into the scruff of the mice. After the first injection,
booster injections were performed three times at two-week
intervals with the same antigen amount but using incomplete
Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO, USA). The
mice were then exsanguinated. The blood was stored at 25uC
overnight and then centrifuged at 3,0006g for 10 min at 4uC. The
antisera were collected and stored at 280uC until use.
RNA isolation and real-time PCR
The total RNA from LMH cells and chicken tissues was
extracted using TRIZOL Reagent (Invitrogen, Carlsbad, CA,
USA) and the SV Total RNA Isolation System (Promega,
Madison, WI, USA), respectively. First-strand cDNA was synthe-
sized using random primers and M-MLV reverse transcriptase
(Promega, Madison, WI, USA). The primers used in real-time







Real-time PCR was performed on an Opticon 2 real-time PCR
system (Bio-Rad, Hercules, CA), according to the manufacturer’s
recommendations. Reactions were performed in a 20-ml volume
containing SYBR Green I Dye. The cycling parameters were
94uC for 2 min, followed by 33 cycles of 94uC for 20 s, 55uC for
20 s and 72uC for 20 s. All samples were analyzed in triplicate and
the expression of the target gene was calculated relative to the





Protein samples from chicken tissues, S9 fractions of transiently
transfected Hela cells and induced bacteria were separated on
10% SDS-PAGE gels and then electrophoretically transferred to
PVDF membranes (PALL, Ann Arbor, MI, USA). The mem-
branes were blocked with freshly prepared TBST buffer (25 mM
Tris-HCl pH 7.5, 150 mM NaCl and 0.1% Tween-20) containing
5% nonfat dry milk for 1 h at room temperature. The membranes
were then incubated for 1 h with the primary antibody in TBST
buffer containing 1% milk, washed three times for 10 min with
TBST, incubated with the secondary antibody for 1 h at room
temperature and then washed for another 30 min with TBST
buffer. The bands were developed for detection with the
LumiGLOH Chemiluminescent Substrate Kit (CST, Beverly,
MA, USA) according to the manufacturer’s instructions. To
confirm the specificity of the anti-CYP2D49 antiserum, the
membranes were incubated with five anti-CYP2D49 antiserum
from five mice, respectively, that had been pre-adsorbed with
excess antigen (purified CYP2D49-Myc-His-Tag fusion protein) at
37uC for 1 h in TBST buffer containing 1% milk. The specific one
was used in the left experiments. When studying the enzymatic
properties of CYP2D49 variants in Hela cells, b-actin was co-
analyzed as the standard on each gel for the quantification of
CYP2D49 and its variants. Chemiluminescence was quantified
using the quantity tool of Image Lab
TM software (Bio-Rad,
Hercules, CA, USA). The dilutions employed for the antibodies
were as follows: polyclonal anti-CYP2D49 antiserum at 1:1500; b-
actin (C4) (sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) at 1:1000; c-Myc (9E10) (sc-40, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 1:1000; HRP-rabbit anti-mouse IgG
(Gamma) (Invitrogen, Carlsbad, CA, USA) at 1:4000.
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Bufuralol is a typical substrate of the CYP2D isoforms. The
level of 19-hydroxybufuralol, a major metabolite of bufuralol, is
often measured as an index of CYP2D activity and/or levels [13].
The bufuralol 19-hydroxylation activity of CYP2D49 was de-
termined by incubating bufuralol with the purified CYP2D49
protein. The incubation mixture contained 100 mg of CYP2D49
protein (protein inactivated by heating for 10 min was used as the
control), 0.2 mM NADPH-P450 reductase, 0.1 mM cytochrome
b5, 0.02 mg/ml liposome (1, 2-dioleoyl-sn-glycero-3-phosphocho-
line, 1, 2-didodecanoyl-rac-glycero-3-phosphocholine and 1, 2-
diacyl-sn-glycero-3-phospho-L-serine mixture), 10 mM MgCl2,2 –
200 mM bufuralol and 100 mM potassium phosphate buffer
(pH 7.4) in a final volume of 250 ml. After a 3-min pre-incubation
at 37uC in a shaking water bath, the reaction was started by
adding NADPH and further incubated at 37uC for 10 min. After
the reaction was stopped by the addition of 20 ml of 60% HClO4
aqueous solution and vortexed, the reaction mixture was
centrifuged at 12,0006g for 5 min at room temperature. An
aliquot (20 ml) of the supernatant was subjected to HPLC analysis
using a Waters 2695 HPLC System (Waters Alliance, Milford,
MA) equipped with a Waters 2475 fluorescence detector. To
separate bufuralol and the bufuralol 19-hydroxylation product, the
samples were injected onto a Hypersil BDS C18 column
(4.66250 mm I.D; particle size 5 mm; Elite, Dalian, China)
equipped with an Analytical Guard Column (3.0620 mm I.D.;
particle size 5 mm; Phenomenex). The mobile phase consisted of
20 mM perchloric acid (pH 2.5) and acetonitrile (65:35, v/v). The
chromatograph was operated at a flow rate of 1 ml/min at room
temperature, with fluorescence detection at 252/302 nm (excita-
tion/emission). A quantitative analysis of the reaction products
was performed using the peak area.
Debrisoquine is a classical substrate for the CYP2D isoforms
and, similar to bufuralol, serves as a probe of CYP2D activity. The
amount of 49-hydroxydebrisoquine transform from debrisoquine is
used to judge the enzymatic activity of CYP2D isoforms [52]. The
incubation conditions were similar to those used with bufuralol
and the detection of 49-hydroxydebrisoquine was performed
according to a published method [21].
The experiments involving inhibition by quinidine were
performed by pre-incubating purified CYP2D49 protein for
5 min at 37uC with 100 mM bufuralol and varying concentrations
of quinidine. The reactions were then started by the addition of
NADPH. The reactions were incubated and the reaction products
were detected as described above.
Expression and enzymatic properties of CYP2D49
variants in Hela cells
The Hela cell line was selected as the recipient cell line because
of its high transient transfection efficiency and its low endogenous
levels of drug metabolism. Before transfection, the Hela cells were
grown overnight to 80% confluence in a 10-cm dish. For each
dish, 24 mg of the expression constructs (pcDNA-CYP2D49, one of
the six mutant constructs or the empty vector) was combined with
60 ml of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in
3 ml of FBS-free DMEM. The transfections were performed in
6 ml of FBS-free DMEM for 6 h. The culture medium was then
replaced with 12 ml of fresh medium (10% FBS in DMEM).
Forty-eight hours after transfection, the cells grown in the culture
medium were rinsed with phosphate-buffered saline (PBS,
pH 7.4), scraped and collected in 100 mM potassium phosphate
buffer (pH 7.4). They were then sonicated with five pulses at 40 W
for 5 s at 10 s intervals. The S9 fractions containing the cytosol
and microsomes are frequently used in assays to measure the
metabolism of drugs and other xenobiotics. Therefore, the cell
homogenate was centrifuged at 9,0006g at 4uC for 20 min to
isolate the S9 fraction, which was then carefully transferred to
a clean tube for western blotting analyses or assays of enzymatic
activity. The protein concentration of S9 fractions were estimated
by the Bradford method.
The bufuralol 19-hydroxylation activity of each S9 fraction was
determined according to a published method [21] with a slight
modification. Briefly, in a brown glass conical tube (2 ml), a 250-ml
incubation mixture was prepared that contained 1.0 mg of
protein, 10 mM MgCl2, 1 mM NADPH and 100 mM bufuralol
in 100 mM potassium phosphate buffer (pH 7.4). After a 3-min
pre-incubation at 37uC,the reaction was started by adding
NADPH and further incubated at 37uC for 10 min. The detection
of 19-hydroxybufuralol was performed as described above.
Circular dichroism spectroscopy
All CYP2D49 variants were assayed at a concentration of 5 mM
in 100 mM potassium phosphate buffer (pH 7.4). The circular
dichroism (CD) spectra of these samples were obtained using the
Chirascan (Applied Photophysics Limited, Leatherhead, Surrey,
UK) at 4uC using a 1.0-nm bandwidth, 1-mm cell, 1.0-nm step,
0.5-s time-per-point and 1.0-min time internal. The thermal
denaturation was monitored at 222 nm by applying a thermal
gradient of 2uC/min over the range from 4 to 92uC. The value for
the buffer alone was measured and subtracted from the protein
spectra. The CD spectra of all of the proteins were acquired as
‘ellipticity’ in millidegrees h. The data were converted to the mean
residue ellipticity ([h] in degree cm
2 dmol
21), as described
previously [32]. The [h] at 222 nm of 233000 deg cm
2 dmol
21
was regarded as representing a 100% helical conformation. The
helical content of the proteins was estimated by dividing the value
of 233000 cm
2 dmol
21 by the [h] value at 222 nm [53].
Data analysis
The standard curve of 19-hydroxybufuralol was calculated using
a linear least-squares regression analysis (MicrosoftH Excel, 2003).
The estimations and statistical analyses of the enzyme kinetic and
inhibition parameters were performed using GraphPad PrismH
software, version 5. Significant differences were evaluated by
ANOVA (significance was defined as p,0.05).
The conformation of CYP2D6 was constructed based on the
crystallographic data of CYP2D6 (2F9Q) obtained from Protein
Data Bank (http://www.rcsb.org/pbd/) and drawn using Accelrys
ViewerLite Version 5.0.
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